Patents by Inventor Je Sang Ko

Je Sang Ko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD133 RELATED TO ANTICANCER AGENT RESISTANCE IN COLON CANCER AND USE THEREOF
    Publication number: 20230265526
    Abstract: The present invention relates to a use of CD133 involved in resistance to an EGFR-targeting agent in colon cancer. The CD133 protein may be used as a novel target protein for diagnosing and treating resistant cancer as well as general cancer.
    Type: Application
    Filed: March 17, 2023
    Publication date: August 24, 2023
    Applicant: Korea University Research and Business Foundation
    Inventors: Je Sang KO, Min-Soo KANG
  • CD133 related to anticancer agent resistance in colon cancer and use thereof
    Patent number: 11639530
    Abstract: The present invention relates to a use of CD133 involved in resistance to an EGFR-targeting agent in colon cancer. The CD133 protein may be used as a novel target protein for diagnosing and treating resistant cancer as well as general cancer.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: May 2, 2023
    Assignee: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Min-Soo Kang
  • PHARMACEUTICAL USE OF ACTININ-4 INVOLVED IN INDUCTION OF CERVICAL CANCER
    Publication number: 20210164982
    Abstract: The present invention relates to a pharmaceutical use of actinin-4 involved in the induction of cervical cancer, and more specifically, characterizes actinin-4 as a marker protein capable of inducing cervical cancer, thereby providing the pharmaceutical use of actinin-4 that can be used in the diagnosis, prevention or treatment of cervical cancer.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 3, 2021
    Applicant: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Hyoung-Tae An
  • CD133 RELATED TO ANTICANCER AGENT RESISTANCE IN COLON CANCER AND USE THEREOF
    Publication number: 20200325545
    Abstract: The present invention relates to a use of CD133 involved in resistance to an EGFR-targeting agent in colon cancer. The CD133 protein may be used as a novel target protein for diagnosing and treating resistant cancer as well as general cancer.
    Type: Application
    Filed: April 14, 2020
    Publication date: October 15, 2020
    Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Je Sang KO, Min-Soo KANG
  • Use of human small leucine zipper protein in osteogenesis procedure
    Patent number: 10456446
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPAR?2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: October 29, 2019
    Assignee: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim
  • Use of human small leucine zipper protein in adipocyte differentiation procedure
    Patent number: 10058586
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPAR?2 to induce the formation of a complex of HDAC3 and PPAR?2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPAR?2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: August 28, 2018
    Assignee: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim
  • PHARMACEUTICAL USE OF ACTININ-4 INVOLVED IN INDUCTION OF CERVICAL CANCER
    Publication number: 20180238887
    Abstract: The present invention relates to a pharmaceutical use of actinin-4 involved in the induction of cervical cancer and more specifically, characterizes actinin-4 as a marker protein capable of inducing cervical cancer, thereby providing the pharmaceutical use of actinin-4 that can be used in the diagnosis, prevention or treatment of cervical cancer.
    Type: Application
    Filed: April 27, 2015
    Publication date: August 23, 2018
    Applicants: Korea University Research and Business Foundation, Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Hyoung-Tae An
  • USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN OSTEOGENESIS PROCEDURE
    Publication number: 20180221443
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPAR?2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.
    Type: Application
    Filed: April 5, 2018
    Publication date: August 9, 2018
    Applicant: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim
  • Use of human small leucine zipper protein in osteogenesis procedure
    Patent number: 9962425
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPAR?2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: May 8, 2018
    Assignee: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim
  • USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN ADIPOCYTE DIFFERENTIATION PROCEDURE
    Publication number: 20180092962
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPAR?2 to induce the formation of a complex of HDAC3 and PPAR?2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPAR?2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.
    Type: Application
    Filed: August 31, 2017
    Publication date: April 5, 2018
    Applicant: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim
  • Use of human small leucine zipper protein in adipocyte differentiation procedure
    Patent number: 9775879
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPAR?2 to induce the formation of a complex of HDAC3 and PPAR?2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPAR?2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: October 3, 2017
    Assignee: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim
  • USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN ADIPOCYTE DIFFERENTIATION PROCEDURE
    Publication number: 20160074471
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPAR?2 to induce the formation of a complex of HDAC3 and PPAR?2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPAR?2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor.
    Type: Application
    Filed: April 30, 2014
    Publication date: March 17, 2016
    Applicant: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim
  • USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN OSTEOGENESIS PROCEDURE
    Publication number: 20160067308
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPAR?2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.
    Type: Application
    Filed: April 30, 2014
    Publication date: March 10, 2016
    Applicant: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim